Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease

@article{Kazim2016NeurotrophicFS,
  title={Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer’s disease},
  author={Syed Faraz Kazim and Khalid Iqbal},
  journal={Molecular Neurodegeneration},
  year={2016},
  volume={11}
}
Alzheimer’s disease (AD) is an incurable and debilitating chronic progressive neurodegenerative disorder which is the leading cause of dementia worldwide. AD is a heterogeneous and multifactorial disorder, histopathologically characterized by the presence of amyloid β (Aβ) plaques and neurofibrillary tangles composed of Aβ peptides and abnormally hyperphosphorylated tau protein, respectively. Independent of the various etiopathogenic mechanisms, neurodegeneration is a final common outcome of AD… 
View on Springer
molecularneurodegeneration.biomedcentral.com
59 Citations
Highly Influential Citations
4
Background Citations
26

59 Citations

Peptides Derived from Growth Factors to Treat Alzheimer’s Disease
TLDR
This review describes the physiological functions of growth factors in the brain, their neuronal signaling pathways, and alteration in AD, and the strategies to develop peptides derived from growth factor and their capacity to mimic the role of native proteins.
New Frontiers in Neurodegeneration and Regeneration Associated with Brain-Derived Neurotrophic Factor and the rs6265 Single Nucleotide Polymorphism
TLDR
There is no “one size fits all” therapy for neurodegenerative or psychiatric disorders and that continued study of the multiple BDNF isoforms and genetic variants represents an avenue for discovery ripe with therapeutic potential.
Targeting BDNF signaling by natural products: novel synaptic repair therapeutics for neurodegeneration and behavior disorders.
Inhibition of formyl peptide receptors improves the outcome in a mouse model of Alzheimer disease
TLDR
It is suggested that the modulation of FPR signaling cascades might be considered as a promising therapeutic approach for alleviating the cognitive deficits associated with early AD.
Role of BACE1 in Alzheimer’s synaptic function
TLDR
It is highly important to understand whether BACE1 inhibition will significantly impact cognitive functions in AD patients, and to guide the proper use of Bace1 inhibitors in AD therapy.
Prognostic Value and Therapeutic Potential of Brain-Derived Neurotrophic Factor (BDNF) in Brain Injuries (Review)
TLDR
The review discusses changes in BDNF levels in ischemic and traumatic brain damage, the prospects of its use in the clinical practice as a marker of brain dysfunction, as well as the possibility of his use for the treatment of post-ischemic encephalopathies.
MicroRNA-140 silencing represses the incidence of Alzheimer's disease
Peptide Derivatives of Erythropoietin in the Treatment of Neuroinflammation and Neurodegeneration.
Novel biomarkers in Alzheimer’s disease using high resolution proteomics and metabolomics: miRNAS, proteins and metabolites
TLDR
The role of several miRNAs identified using genomic technologies, and the importance of novel proteomic and metabolomic approaches to identify new proteins and metabolites that may be useful as biomarkers for monitoring the progression and treatment of AD are discussed.
Neurotrophic Treatment Initiated During Early Postnatal Development Prevents the Alzheimer-Like Behavior and Synaptic Dysfunction
TLDR
Findings indicate that treatment with the neurotrophic peptide mimetic such as P021 during early development can be an effective therapeutic strategy to rescue synaptic deficit and cognitive impairment in familial AD and related tauopathies.
...
...

References

SHOWING 1-10 OF 217 REFERENCES
Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
Ciliary Neurotrophic Factor Cell-Based Delivery Prevents Synaptic Impairment and Improves Memory in Mouse Models of Alzheimer's Disease
TLDR
Preclinical studies suggest that CNTF and/or CNTF receptor-associated pathways may have AD-modifying activity through protection against progressive Aβ-related memory deficits and encourage additional exploration of ex vivo gene transfer for the prevention and/ or treatment of AD.
A small molecule p75NTR ligand prevents cognitive deficits and neurite degeneration in an Alzheimer’s mouse model
Opportunities and challenges in developing Alzheimer disease therapeutics
TLDR
An increasing number of preclinical studies in transgenic mouse models of AD show that enhancement of neurogenesis and neuronal plasticity can reverse cognitive impairment, and development of both drugs that can inhibit neurodegeneration and drug that can increase the regenerative capacity of the brain by enhancing neuroGenesis and neurons plasticity are required to control AD.
Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents.
TLDR
It is proposed that these compounds constitute a novel group of tools for the study of TrkB signaling and may provide leads for developing new therapeutic agents for neurodegenerative diseases.
Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice
TLDR
Peripheral administration of Peptide 6, an 11-mer, which makes an active region of ciliary neurotrophic factor (CNTF, amino acid residues 146–156), restored cognition by enhancing neurogenesis and neuronal plasticity in these mice.
Shifting balance from neurodegeneration to regeneration of the brain: a novel therapeutic approach to Alzheimer's disease and related neurodegenerative conditions
TLDR
One potential rational therapeutic approach to AD and other neurodegenerative conditions is to provide a neurotrophic environment in the brain that can materialize into successful neurogenesis and rescue neuronal plasticity deficit.
Enhancement of neurogenesis and memory by a neurotrophic peptide in mild to moderate traumatic brain injury.
TLDR
Long-term treatment with Peptide 6 enhances the pool of newborn neurons in the dentate gyrus, prevents neuronal loss in CA1 and parietal cortex, preserves the dendritic and synaptic architecture in the hippocampus, and improves performance on a hippocampus-dependent memory task in TBI mice.
Molecular mechanisms of neurodegeneration in Alzheimer's disease.
TLDR
Several lines of investigation support the notion that the synaptic pathology and defective neurogenesis in AD are related to progressive accumulation of Abeta oligomers rather than fibrils.
Small molecules activating TrkB receptor for treating a variety of CNS disorders.
TLDR
A survey of the various strategies taken towards the development of small molecule mimetics for BDNF and the selective TrkB agonist 7, 8-dihydroxyflavone, which modulates multiple functions and has demonstrated remarkable therapeutic efficacy in a variety of central nervous system disease models is provided.
...
...